Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose
Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, Fedorova T, Proudman SM, James M, Cleland LG, Jones G
Annals of the rheumatic diseases · 100 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Arthritis Australia
- Gobierno
- Medical Research Council
- Gobierno
- National Health and Medical Research Council
- Subvenciones
- National Health and Medical Research Council (451900)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2015-10-21 · Ann Rheum Dis · vol. 75 · número 1 · págs. 23–29
- Editorial
- BMJ
- Citado
- 143 citas · más que el 99% de estudios similares · 10.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 44 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Osteoarthritis Treatment and Mechanisms · Fatty Acid Research and Health · Pharmacological Effects of Medicinal Plants
- Palabras clave
- knee osteoarthritis, fish oil, omega-3 fatty acids, dose comparison, low-dose supplementation, WOMAC pain, cartilage volume loss, bone marrow lesions, analgesic use, NSAID use, quality of life
- MeSH
- cartilage, articular, humans, arthralgia, osteoarthritis, knee, acetaminophen, fatty acids, omega-3, analgesics, anti-inflammatory agents, non-steroidal, magnetic resonance imaging, pain measurement, organ size, double-blind method, quality of life, dietary supplements, aged, middle aged, female, male, musculoskeletal pain
11 autores
- Catherine Louise Hill🇦🇺 · autor de correspondenciaQueen Elizabeth Hospital; The University of Adelaide
- LYN M. MARCH🇦🇺Royal North Shore Hospital
- Dawn A. Aitken
- Susan Elizabeth Lester🇦🇺Queen Elizabeth Hospital
- Ruth Battersby🇦🇺Queen Elizabeth Hospital
- K Hynes
- Tanya Fedorova🇦🇺Royal North Shore Hospital
- Susanna Proudman🇦🇺Royal Adelaide Hospital
- Michael J. James🇦🇺Royal Adelaide Hospital
- Leslie G. Cleland🇦🇺Royal Adelaide Hospital
- Graeme Jones
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
To determine whether high-dose fish oil is superior to low-dose supplementation for symptomatic and structural outcomes in knee osteoarthritis (OA).
Methods
A randomised, double-blind, multicentre trial enrolled 202 patients with knee OA and regular knee pain. They were randomised 1:1 to high-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day or (2) low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day. The primary endpoints were Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score at 3, 6, 12 and 24 months, and change in cartilage volume at 24 months. Secondary outcomes included WOMAC function, quality of life, analgesic and non-steroidal anti-inflammatory drug use and bone marrow lesion score.
Results
Although there was improvement in both groups, the low-dose fish oil group had greater improvement in WOMAC pain and function scores at 2 years compared with the high-dose group, whereas between-group differences at 1 year did not reach statistical significance. There was no difference between the two groups in cartilage volume loss at 2 years. For other secondary endpoints, there was no difference between the two groups at 2 years.
Conclusions
In people with symptomatic knee OA, there was no additional benefit of a high-dose fish oil compared with low-dose fish oil. The combination comparator oil appeared to have better efficacy in reducing pain at 2 years, suggesting that this requires further investigation.
Trial registration number
Australian New Zealand Clinical Trials Registry (ACTRN 12607000415404).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.